Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) will report first quarter 2026 financial results on April 30, 2026. The company will host a video conference call and webcast at 8:30 a.m. ET that day. Registration and a replay will be available via the Investors section at www.kymeratx.com.

News Market Reaction – KYMR

-1.80%

-1.80% Session close to close

In the Apr 23 session, KYMR declined 1.80%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the Q1 2026 earnings and webcast for April 30, 2026, continuing Kymera’s patt...

Analysis

This announcement sets the Q1 2026 earnings and webcast for April 30, 2026, continuing Kymera’s pattern of clearly telegraphing financial and clinical update dates. Historically, similar timing releases around earnings and KT-621 data have coincided with notable price moves, while recent filings reflect active insider trading plans. Investors may focus on how upcoming results relate to prior milestones, cash runway, and partnerships disclosed in earlier updates.

Key Figures

Earnings date: April 30, 2026 Quarter reported: First quarter 2026 Earnings call time: 8:30 a.m. ET

3 metrics

Earnings date April 30, 2026 Q1 2026 financial results release date

Quarter reported First quarter 2026 Period covered by upcoming results

Earnings call time 8:30 a.m. ET Scheduled time for video conference call and webcast

Previous Earnings date Reports

2 past events · Latest: Feb 19 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 19	Earnings date notice	Positive	+1.6%	Announcement of Q4 and full-year 2025 earnings release timing and webcast details.
Dec 05	Data release timing	Positive	+41.5%	Scheduling of KT-621 BroADen Phase 1b topline atopic dermatitis results and call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Past 'earnings date' and data-timing announcements have tended to coincide with positive price reactions, sometimes strongly so.

Recent Company History

Recent events show Kymera combining clinical and financial milestones. On Feb 26, 2026, Q4 and full-year 2025 results plus a business update led to a 4.8% move, supported by $1.6 billion cash and KT-621 Fast Track status. Gilead’s KT-200 option on Apr 9, 2026 added a $45 million milestone and up to $750 million in potential payments. Today’s Q1 2026 earnings date notice fits this cadence of scheduled value updates.

Key Terms

clinical-stage biopharmaceutical, oral small molecule degrader

2 terms

clinical-stage biopharmaceutical medical

"Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company"

A clinical-stage biopharmaceutical is a company that is developing medicines or biological treatments that are currently being tested in people in clinical trials to assess safety and effectiveness. For investors it signals a higher-risk, higher-reward profile: progress through human testing and regulatory milestones can sharply increase value if results are positive, while failed trials can wipe out expected future revenue — like a prototype that must prove it works before it can be sold widely.

oral small molecule degrader medical

"advancing a new class of oral small molecule degrader medicines for immunological diseases"

An oral small molecule degrader is a pill-form drug that binds to a specific disease-related protein and sends it to the cell’s natural disposal system so the protein is broken down and removed. For investors, these drugs represent a different way to tackle targets that were hard to block with traditional drugs, so successful clinical results can change a company’s prospects quickly—think of swapping a bandage for a vacuum that removes the root cause.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report first quarter 2026 financial results on April 30, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. 

To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.

About Kymera Therapeutics 
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Investor Contact: 
Justine Koenigsberg
investors@kymeratx.com
857-285-5300 

Media Contact:
Matthew Henson
mhenson@kymeratx.com
857-285-5300

FAQ

When will Kymera Therapeutics (KYMR) report Q1 2026 results?

Kymera will report Q1 2026 financial results on April 30, 2026. According to the company, the release coincides with a video conference call and webcast scheduled for 8:30 a.m. ET the same day.

How can investors join the Kymera (KYMR) April 30, 2026 webcast?

Investors can join by registering via the company’s events link or visiting the Investors section at www.kymeratx.com. According to the company, registration is required to access the live video conference and livestreamed webcast.

What time is Kymera Therapeutics (KYMR) conference call for Q1 2026?

The conference call and webcast will begin at 8:30 a.m. ET on April 30, 2026. According to the company, a replay of the webcast will be archived and available after the event on the investor website.

Will Kymera (KYMR) provide a replay of the April 30, 2026 webcast?

Yes. A replay of the webcast will be archived and available following the event on the company’s investor website. According to the company, registered attendees can also access the livestream and later view the archived recording.

Where can I find materials for Kymera (KYMR) Q1 2026 earnings presentation?

Presentation materials and the webcast link will be posted in the Investors > News and Events section at www.kymeratx.com. According to the company, the site will host registration, the live webcast, and the archived replay after the call.